BioCentury
ARTICLE | Clinical News

Elagolix: Phase II data

December 21, 2009 8:00 AM UTC

Top-line 3-month data from the double-blind, international Phase II Tulip PETAL trial in 174 patients showed that 150 and 250 mg once-daily elagolix and Prostap SR leuprorelin significantly improved s...